Skip to main content
Erschienen in: Annals of Surgical Oncology 13/2014

01.12.2014 | Gynecologic Oncology

Significance of Adenomyosis on Tumor Progression and Survival Outcome of Endometrial Cancer

verfasst von: Koji Matsuo, MD, PhD, Sigita S. Cahoon, MD, Marc Gualtieri, MD, Christopher A. Scannell, PhD, Carrie E. Jung, MD, Tadao Takano, MD, PhD, Richard J. Paulson, MD, Laila I. Muderspach, MD, Lynda D. Roman, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 13/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

To examine the effects of adenomyosis on tumor progression and survival outcome of endometrial cancer patients.

Methods

This is a retrospective study examining stage I–IV endometrial cancer patients who underwent hysterectomy-based surgical staging (n = 571), and endometrial hyperplasia patients who underwent hysterectomy (n = 213). Clinical demographics, histopathological factors, and survival outcomes were analyzed based on the presence or absence of adenomyosis.

Results

Among the endometrial cancer cohort, adenomyosis was observed in 47.5 % of cases and was significantly associated with lower grade (grade 1–2 tumors, 81.2 vs. 73.3 %; p = 0.028), earlier stage (stage I disease, 74.8 vs. 64.3 %; p = 0.023), and lower likelihood of deep myometrial invasion (19.2 vs. 28.2 %; p = 0.039) and cervical invasion (13.7 vs. 21.2 %; p = 0.024) than those without adenomyosis. In survival analysis, endometrial cancer coexisting with adenomyosis was associated with a significantly better disease-free survival (5-year rate, 89.2 vs. 78.2 %; p < 0.001) and overall survival (91.8 vs. 83.9 %; p = 0.004) after hysterectomy. In multivariate analysis, controlling for other significant variables in univariate analysis, presence of adenomyosis remained an independent prognostic factor associated with decreased risk of disease recurrence after surgery (hazard ratio [HR] 0.53; 95 % confidence interval [CI] 0.30–0.92; p = 0.023). Endometrial hyperplasia had a significantly increased incidence of adenomyosis when compared with type I endometrial cancer (grade 1–2 endometrioid adenocarcinoma, n = 411) on multivariate analysis (62.9 vs. 48.9 %; HR 1.88; 95 % CI 1.32–2.69; p < 0.001).

Conclusions

Adenomyosis appears to be associated with less aggressive tumor behavior of endometrial cancer, suggesting that it may have inhibitory effects on the progression of this disease.
Literatur
1.
2.
Zurück zum Zitat Wright JD, Barrena Medel NI, Sehouli J, Fujiwara K, Herzog TJ. Contemporary management of endometrial cancer. Lancet. 2012;379:1352–60.PubMedCrossRef Wright JD, Barrena Medel NI, Sehouli J, Fujiwara K, Herzog TJ. Contemporary management of endometrial cancer. Lancet. 2012;379:1352–60.PubMedCrossRef
3.
Zurück zum Zitat Garcia L, Isaacson K. Adenomyosis: review of the literature. J Minim Invasive Gynecol. 2011;18:428–37.PubMedCrossRef Garcia L, Isaacson K. Adenomyosis: review of the literature. J Minim Invasive Gynecol. 2011;18:428–37.PubMedCrossRef
4.
Zurück zum Zitat Kairi-Vassilatou E, Kontogianni K, Salamalekis M, Sykiotis K, Kondi-Pafitis A. A clinicopathological study of the relationship between adenomyosis and other hormone-dependent uterine lesions. Eur J Gynaecol Oncol. 2004;25:222–4.PubMed Kairi-Vassilatou E, Kontogianni K, Salamalekis M, Sykiotis K, Kondi-Pafitis A. A clinicopathological study of the relationship between adenomyosis and other hormone-dependent uterine lesions. Eur J Gynaecol Oncol. 2004;25:222–4.PubMed
5.
Zurück zum Zitat Winkelman J, Robinson R. Adenocarcinoma of endometrium involving adenomyosis. Report of an unusual case and review of the literature. Cancer. 1966;19:901–8.PubMedCrossRef Winkelman J, Robinson R. Adenocarcinoma of endometrium involving adenomyosis. Report of an unusual case and review of the literature. Cancer. 1966;19:901–8.PubMedCrossRef
6.
Zurück zum Zitat Hernandez E, Woodruff JD. Endometrial adenocarcinoma arising in adenomyosis. Am J Obstet Gynecol. 1980;138:827–32.PubMed Hernandez E, Woodruff JD. Endometrial adenocarcinoma arising in adenomyosis. Am J Obstet Gynecol. 1980;138:827–32.PubMed
7.
Zurück zum Zitat Woodruff JD, Erozan YS, Genadry R. Adenocarcinoma arising in adenomyosis detected by atypical cytology. Obstet Gynecol. 1986;67:145–8.PubMed Woodruff JD, Erozan YS, Genadry R. Adenocarcinoma arising in adenomyosis detected by atypical cytology. Obstet Gynecol. 1986;67:145–8.PubMed
8.
Zurück zum Zitat Kuwashima Y, Uehara T, Kishi K, et al. Intramural adenocarcinoma of the uterus, arisen from adenomyosis uteri, showing unique histologic appearances. Report of two cases. Eur J Gynaecol Oncol. 1994;15:418–23.PubMed Kuwashima Y, Uehara T, Kishi K, et al. Intramural adenocarcinoma of the uterus, arisen from adenomyosis uteri, showing unique histologic appearances. Report of two cases. Eur J Gynaecol Oncol. 1994;15:418–23.PubMed
9.
Zurück zum Zitat Hayata T, Tanaka Y, Miyakawa I. Endometrial cancer associated with adenomyosis. Int J Gynaecol Obstet. 1994;44:76–7.PubMedCrossRef Hayata T, Tanaka Y, Miyakawa I. Endometrial cancer associated with adenomyosis. Int J Gynaecol Obstet. 1994;44:76–7.PubMedCrossRef
10.
Zurück zum Zitat Takai N, Akizuki S, Nasu K, Etoh Y, Miyakawa I. Endometrioid adenocarcinoma arising from adenomyosis. Gynecol Obstet Invest. 1999;48:141–4.PubMedCrossRef Takai N, Akizuki S, Nasu K, Etoh Y, Miyakawa I. Endometrioid adenocarcinoma arising from adenomyosis. Gynecol Obstet Invest. 1999;48:141–4.PubMedCrossRef
11.
Zurück zum Zitat Sasaki T, Sugiyama T, Nanjo H, et al. Endometrioid adenocarcinoma arising from adenomyosis: report and immunohistochemical analysis of an unusual case. Pathol Int. 2001;51:308–13.PubMedCrossRef Sasaki T, Sugiyama T, Nanjo H, et al. Endometrioid adenocarcinoma arising from adenomyosis: report and immunohistochemical analysis of an unusual case. Pathol Int. 2001;51:308–13.PubMedCrossRef
12.
Zurück zum Zitat Ichikawa Y, Takano K, Higa S, et al. Endometrial carcinoma coexisting with pregnancy, presumed to derive from adenomyosis: a case report. Int J Gynecol Cancer. 2001;11:488–90.PubMedCrossRef Ichikawa Y, Takano K, Higa S, et al. Endometrial carcinoma coexisting with pregnancy, presumed to derive from adenomyosis: a case report. Int J Gynecol Cancer. 2001;11:488–90.PubMedCrossRef
13.
Zurück zum Zitat Koshiyama M, Suzuki A, Ozawa M, et al. Adenocarcinomas arising from uterine adenomyosis: a report of four cases. Int J Gynecol Pathol. 2002;21:239–45.PubMedCrossRef Koshiyama M, Suzuki A, Ozawa M, et al. Adenocarcinomas arising from uterine adenomyosis: a report of four cases. Int J Gynecol Pathol. 2002;21:239–45.PubMedCrossRef
14.
Zurück zum Zitat Couto D, Mota F, Silva T, de Oliveira C. Adenocarcinoma arising in adenomyosis: report of an unusual case. Acta Obstet Gynecol Scand. 2004;83:406–8.PubMedCrossRef Couto D, Mota F, Silva T, de Oliveira C. Adenocarcinoma arising in adenomyosis: report of an unusual case. Acta Obstet Gynecol Scand. 2004;83:406–8.PubMedCrossRef
15.
Zurück zum Zitat Takeuchi K, Yamanaka Y, Hamana S, Ohara N, Maruo T. Invasive adenocarcinoma arising from uterine adenomyosis involving the rectosigmoid colon. Int J Gynecol Cancer. 2004;14:1004–6.PubMedCrossRef Takeuchi K, Yamanaka Y, Hamana S, Ohara N, Maruo T. Invasive adenocarcinoma arising from uterine adenomyosis involving the rectosigmoid colon. Int J Gynecol Cancer. 2004;14:1004–6.PubMedCrossRef
16.
Zurück zum Zitat Hsu MI, Chou SY, Lin SE, Liang SJ, Chiu HC, Hsu CS. Very early stage adenocarcinoma arising from adenomyosis in the uterus. Taiwan J Obstet Gynecol. 2006;45:346–9.PubMedCrossRef Hsu MI, Chou SY, Lin SE, Liang SJ, Chiu HC, Hsu CS. Very early stage adenocarcinoma arising from adenomyosis in the uterus. Taiwan J Obstet Gynecol. 2006;45:346–9.PubMedCrossRef
17.
Zurück zum Zitat Izadi-Mood N, Samadi N, Sarmadi S, Eftekhar Z. Papillary serous carcinoma arising from adenomyosis presenting as intramural leiomyoma. Arch Iran Med. 2007;10:258–60.PubMed Izadi-Mood N, Samadi N, Sarmadi S, Eftekhar Z. Papillary serous carcinoma arising from adenomyosis presenting as intramural leiomyoma. Arch Iran Med. 2007;10:258–60.PubMed
18.
Zurück zum Zitat Ismiil ND, Rasty G, Ghorab Z, et al. Adenomyosis is associated with myometrial invasion by FIGO 1 endometrial adenocarcinoma. Int J Gynecol Pathol. 2007;26:278–83.PubMedCrossRef Ismiil ND, Rasty G, Ghorab Z, et al. Adenomyosis is associated with myometrial invasion by FIGO 1 endometrial adenocarcinoma. Int J Gynecol Pathol. 2007;26:278–83.PubMedCrossRef
19.
20.
Zurück zum Zitat Ismiil N, Rasty G, Ghorab Z, et al. Adenomyosis involved by endometrial adenocarcinoma is a significant risk factor for deep myometrial invasion. Ann Diagn Pathol. 2007;11:252–7.PubMedCrossRef Ismiil N, Rasty G, Ghorab Z, et al. Adenomyosis involved by endometrial adenocarcinoma is a significant risk factor for deep myometrial invasion. Ann Diagn Pathol. 2007;11:252–7.PubMedCrossRef
21.
Zurück zum Zitat Ohta Y, Hamatani S, Suzuki T, et al. Clear cell adenocarcinoma arising from a giant cystic adenomyosis: a case report with immunohistochemical analysis of laminin-5 gamma2 chain and p53 overexpression. Pathol Res Pract. 2008;204:677–82.PubMedCrossRef Ohta Y, Hamatani S, Suzuki T, et al. Clear cell adenocarcinoma arising from a giant cystic adenomyosis: a case report with immunohistochemical analysis of laminin-5 gamma2 chain and p53 overexpression. Pathol Res Pract. 2008;204:677–82.PubMedCrossRef
22.
Zurück zum Zitat Motohara K, Tashiro H, Ohtake H, Saito F, Ohba T, Katabuchi H. Endometrioid adenocarcinoma arising in adenomyosis: elucidation by periodic magnetic resonance imaging evaluations. Int J Clin Oncol. 2008;13:266–70.PubMedCrossRef Motohara K, Tashiro H, Ohtake H, Saito F, Ohba T, Katabuchi H. Endometrioid adenocarcinoma arising in adenomyosis: elucidation by periodic magnetic resonance imaging evaluations. Int J Clin Oncol. 2008;13:266–70.PubMedCrossRef
23.
Zurück zum Zitat Hirabayashi K, Yasuda M, Kajiwara H, et al. Clear cell adenocarcinoma arising from adenomyosis. Int J Gynecol Pathol. 2009;28:262–6.PubMedCrossRef Hirabayashi K, Yasuda M, Kajiwara H, et al. Clear cell adenocarcinoma arising from adenomyosis. Int J Gynecol Pathol. 2009;28:262–6.PubMedCrossRef
24.
Zurück zum Zitat Kazandi M, Zeybek B, Terek MC, Zekioglu O, Ozdemir N, Oztekin K. Grade 2 endometrioid adenocarcinoma arising from adenomyosis of the uterus: report of a case. Eur J Gynaecol Oncol. 2010;31:719–21.PubMed Kazandi M, Zeybek B, Terek MC, Zekioglu O, Ozdemir N, Oztekin K. Grade 2 endometrioid adenocarcinoma arising from adenomyosis of the uterus: report of a case. Eur J Gynaecol Oncol. 2010;31:719–21.PubMed
25.
Zurück zum Zitat Abushahin N, Zhang T, Chiang S, Zhang X, Hatch K, Zheng W. Serous endometrial intraepithelial carcinoma arising in adenomyosis: a report of 5 cases. Int J Gynecol Pathol. 2011;30:271–81.PubMedCrossRef Abushahin N, Zhang T, Chiang S, Zhang X, Hatch K, Zheng W. Serous endometrial intraepithelial carcinoma arising in adenomyosis: a report of 5 cases. Int J Gynecol Pathol. 2011;30:271–81.PubMedCrossRef
26.
Zurück zum Zitat Kucera E, Hejda V, Dankovcik R, Valha P, Dudas M, Feyereisl J. Malignant changes in adenomyosis in patients with endometrioid adenocarcinoma. Eur J Gynaecol Oncol. 2011;32:182–4.PubMed Kucera E, Hejda V, Dankovcik R, Valha P, Dudas M, Feyereisl J. Malignant changes in adenomyosis in patients with endometrioid adenocarcinoma. Eur J Gynaecol Oncol. 2011;32:182–4.PubMed
27.
Zurück zum Zitat Boes AS, Tousseyn T, Vandenput I, et al. Pitfall in the diagnosis of endometrial cancer: case report of an endometrioid adenocarcinoma arising from uterine adenomyosis. Eur J Gynaecol Oncol. 2011;32:431–4.PubMed Boes AS, Tousseyn T, Vandenput I, et al. Pitfall in the diagnosis of endometrial cancer: case report of an endometrioid adenocarcinoma arising from uterine adenomyosis. Eur J Gynaecol Oncol. 2011;32:431–4.PubMed
28.
Zurück zum Zitat Quick CM, May T, Horowitz NS, Nucci MR. Low-grade, low-stage endometrioid endometrial adenocarcinoma: a clinicopathologic analysis of 324 cases focusing on frequency and pattern of myoinvasion. Int J Gynecol Pathol. 2012;31:337–43.PubMedCrossRef Quick CM, May T, Horowitz NS, Nucci MR. Low-grade, low-stage endometrioid endometrial adenocarcinoma: a clinicopathologic analysis of 324 cases focusing on frequency and pattern of myoinvasion. Int J Gynecol Pathol. 2012;31:337–43.PubMedCrossRef
29.
Zurück zum Zitat Hanley KZ, Dustin SM, Stoler MH, Atkins KA. The significance of tumor involved adenomyosis in otherwise low-stage endometrioid adenocarcinoma. Int J Gynecol Pathol. 2010;29:445–51.PubMedCrossRef Hanley KZ, Dustin SM, Stoler MH, Atkins KA. The significance of tumor involved adenomyosis in otherwise low-stage endometrioid adenocarcinoma. Int J Gynecol Pathol. 2010;29:445–51.PubMedCrossRef
30.
Zurück zum Zitat Hall JB, Young RH, Nelson JH Jr. The prognostic significance of adenomyosis in endometrial carcinoma. Gynecol Oncol. 1984;17:32–40.PubMedCrossRef Hall JB, Young RH, Nelson JH Jr. The prognostic significance of adenomyosis in endometrial carcinoma. Gynecol Oncol. 1984;17:32–40.PubMedCrossRef
31.
Zurück zum Zitat Jacques SM, Lawrence WD. Endometrial adenocarcinoma with variable-level myometrial involvement limited to adenomyosis: a clinicopathologic study of 23 cases. Gynecol Oncol. 1990;37:401–7.PubMedCrossRef Jacques SM, Lawrence WD. Endometrial adenocarcinoma with variable-level myometrial involvement limited to adenomyosis: a clinicopathologic study of 23 cases. Gynecol Oncol. 1990;37:401–7.PubMedCrossRef
32.
Zurück zum Zitat Mittal KR, Barwick KW. Endometrial adenocarcinoma involving adenomyosis without true myometrial invasion is characterized by frequent preceding estrogen therapy, low histologic grades, and excellent prognosis. Gynecol Oncol. 1993;49:197–201.PubMedCrossRef Mittal KR, Barwick KW. Endometrial adenocarcinoma involving adenomyosis without true myometrial invasion is characterized by frequent preceding estrogen therapy, low histologic grades, and excellent prognosis. Gynecol Oncol. 1993;49:197–201.PubMedCrossRef
33.
Zurück zum Zitat Koshiyama M, Okamoto T, Ueta M. The relationship between endometrial carcinoma and coexistent adenomyosis uteri, endometriosis externa and myoma uteri. Cancer Detect Prev. 2004;28:94–8.PubMedCrossRef Koshiyama M, Okamoto T, Ueta M. The relationship between endometrial carcinoma and coexistent adenomyosis uteri, endometriosis externa and myoma uteri. Cancer Detect Prev. 2004;28:94–8.PubMedCrossRef
34.
Zurück zum Zitat Musa F, Frey MK, Im HB, Chekmareva M, Ellenson LH, Holcomb K. Does the presence of adenomyosis and lymphovascular space invasion affect lymph node status in patients with endometrioid adenocarcinoma of the endometrium? Am J Obstet Gynecol. 2012;207:417.e1-6.PubMedCrossRef Musa F, Frey MK, Im HB, Chekmareva M, Ellenson LH, Holcomb K. Does the presence of adenomyosis and lymphovascular space invasion affect lymph node status in patients with endometrioid adenocarcinoma of the endometrium? Am J Obstet Gynecol. 2012;207:417.e1-6.PubMedCrossRef
35.
Zurück zum Zitat Gun I, Oner O, Bodur S, Ozdamar O, Atay V. Is adenomyosis associated with the risk of endometrial cancer? Med Glas (Zenica). 2012;9:268–72.PubMed Gun I, Oner O, Bodur S, Ozdamar O, Atay V. Is adenomyosis associated with the risk of endometrial cancer? Med Glas (Zenica). 2012;9:268–72.PubMed
36.
Zurück zum Zitat Sotnikova N, Antsiferova I, Malyshkina A. Cytokine network of eutopic and ectopic endometrium in women with adenomyosis. Am J Reprod Immunol. 2002;47:251–5.PubMedCrossRef Sotnikova N, Antsiferova I, Malyshkina A. Cytokine network of eutopic and ectopic endometrium in women with adenomyosis. Am J Reprod Immunol. 2002;47:251–5.PubMedCrossRef
37.
Zurück zum Zitat Wang F, Li H, Yang Z, Du X, Cui M, Wen Z. Expression of interleukin-10 in patients with adenomyosis. Fertil Steril. 2009;91:1681–5.PubMedCrossRef Wang F, Li H, Yang Z, Du X, Cui M, Wen Z. Expression of interleukin-10 in patients with adenomyosis. Fertil Steril. 2009;91:1681–5.PubMedCrossRef
38.
Zurück zum Zitat Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002;13:95–109.PubMedCrossRef Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002;13:95–109.PubMedCrossRef
39.
Zurück zum Zitat Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie. 2007;89:884–93.PubMedCrossRef Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie. 2007;89:884–93.PubMedCrossRef
40.
Zurück zum Zitat van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist. 2006;11:397–408.PubMedCrossRef van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist. 2006;11:397–408.PubMedCrossRef
41.
Zurück zum Zitat Tagashira Y, Taniguchi F, Harada T, Ikeda A, Watanabe A, Terakawa N. Interleukin-10 attenuates TNF-alpha-induced interleukin-6 production in endometriotic stromal cells. Fertil Steril. 2009;91:2185–92.PubMedCrossRef Tagashira Y, Taniguchi F, Harada T, Ikeda A, Watanabe A, Terakawa N. Interleukin-10 attenuates TNF-alpha-induced interleukin-6 production in endometriotic stromal cells. Fertil Steril. 2009;91:2185–92.PubMedCrossRef
42.
Zurück zum Zitat Zitvogel L, Kepp O, Galluzzi L, Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol. 2012;13:343–51.PubMedCrossRef Zitvogel L, Kepp O, Galluzzi L, Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol. 2012;13:343–51.PubMedCrossRef
43.
Zurück zum Zitat Palena C, Hamilton DH, Fernando RI. Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment. Future Oncol. 2012;8:713–22.PubMedCentralPubMedCrossRef Palena C, Hamilton DH, Fernando RI. Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment. Future Oncol. 2012;8:713–22.PubMedCentralPubMedCrossRef
44.
Zurück zum Zitat Yang JH, Wu MY, Chen CD, Chen MJ, Yang YS, Ho HN. Altered apoptosis and proliferation in endometrial stromal cells of women with adenomyosis. Hum Reprod. 2007;22:945–52.PubMedCrossRef Yang JH, Wu MY, Chen CD, Chen MJ, Yang YS, Ho HN. Altered apoptosis and proliferation in endometrial stromal cells of women with adenomyosis. Hum Reprod. 2007;22:945–52.PubMedCrossRef
45.
Zurück zum Zitat Mehasseb MK, Bell SC, Brown L, Pringle JH, Habiba M. Phenotypic characterisation of the inner and outer myometrium in normal and adenomyotic uteri. Gynecol Obstet Invest. 2011;71:217–24.PubMedCrossRef Mehasseb MK, Bell SC, Brown L, Pringle JH, Habiba M. Phenotypic characterisation of the inner and outer myometrium in normal and adenomyotic uteri. Gynecol Obstet Invest. 2011;71:217–24.PubMedCrossRef
46.
Zurück zum Zitat Benagiano G, Habiba M, Brosens I. The pathophysiology of uterine adenomyosis: an update. Fertil Steril. 2012;98:572–9.PubMedCrossRef Benagiano G, Habiba M, Brosens I. The pathophysiology of uterine adenomyosis: an update. Fertil Steril. 2012;98:572–9.PubMedCrossRef
47.
Zurück zum Zitat Vercellini P, Vigano P, Somigliana E, Daguati R, Abbiati A, Fedele L. Adenomyosis: epidemiological factors. Best Pract Res Clin Obstet Gynaecol. 2006;20:465–77.PubMedCrossRef Vercellini P, Vigano P, Somigliana E, Daguati R, Abbiati A, Fedele L. Adenomyosis: epidemiological factors. Best Pract Res Clin Obstet Gynaecol. 2006;20:465–77.PubMedCrossRef
48.
Zurück zum Zitat Koike N, Tsunemi T, Uekuri C, et al. Pathogenesis and malignant transformation of adenomyosis (review). Oncol Rep. 2013;29:861–7.PubMed Koike N, Tsunemi T, Uekuri C, et al. Pathogenesis and malignant transformation of adenomyosis (review). Oncol Rep. 2013;29:861–7.PubMed
Metadaten
Titel
Significance of Adenomyosis on Tumor Progression and Survival Outcome of Endometrial Cancer
verfasst von
Koji Matsuo, MD, PhD
Sigita S. Cahoon, MD
Marc Gualtieri, MD
Christopher A. Scannell, PhD
Carrie E. Jung, MD
Tadao Takano, MD, PhD
Richard J. Paulson, MD
Laila I. Muderspach, MD
Lynda D. Roman, MD
Publikationsdatum
01.12.2014
Verlag
Springer US
Erschienen in
Annals of Surgical Oncology / Ausgabe 13/2014
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3880-6

Weitere Artikel der Ausgabe 13/2014

Annals of Surgical Oncology 13/2014 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.